The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting

被引:91
|
作者
Ciechanover, A [1 ]
机构
[1] Technion Israel Inst Technol, Dept Biochem, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
关键词
cancer; neurodegeneration; protein degradation; proteasome; ubiquitin;
D O I
10.1042/BST0310474
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Until the early 1980s, protein degradation was a neglected research area, and scientists were mostly busy deciphering the genetic code and its translation to the proteome. Destruction of cellular proteins was thought to be a scavenger, non-specific and dead-end process. Although it was known that proteins do turn over, the large extent and high specificity of the process, whereby distinct proteins have half-lives that range from a few minutes to several days, was not appreciated. The discovery of the lysosome by Christian de Duve did not change this view significantly, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. it is clear now that degradation of cellular proteins via the ubiquitin system is a highly complex, temporally controlled and tightly regulated process that plays major roles in a variety of basic pathways and processes during cell life and death, and in health and disease. The system is involved in targeting many cellular proteins, among them cell cycle regulators, growth- and differentiation-controlling factors, transcriptional activators, cell-surface receptors and ion channels, endoplasmic reticulum proteins, antigenic proteins destined for presentation on class I MHC molecules, and abnormal/misfolded proteins. Consequently, it is involved in regulating many basic cellular processes, such as cell cycle and division, growth and differentiation, signal transduction and transcription, modulation of the secretory and endocytic pathways, the immune and inflammatory responses, and quality control. With the multitude of substrates targeted and the numerous processes involved, it is not surprising that aberrations in the pathway have been implicated in the pathogenesis of many diseases, with certain malignancies and neurodegenerative disorders being ranked among them.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [41] Imitative Neural Mechanism-Based Behavior Intention Recognition System in Human-Robot Interaction
    Ko, Kwang-Eun
    Sim, Kwee-Bo
    [J]. INTERNATIONAL JOURNAL OF HUMANOID ROBOTICS, 2014, 11 (04)
  • [42] A novel therapeutic strategy for effective elimination of glioblastoma stem cells using biochemical mechanism-based drug combinations
    Yuan, S.
    Wang, F.
    Wang, L.
    Zhang, H.
    Chen, G.
    Feng, L.
    Xu, R.
    Wang, J.
    Huang, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Novel drug delivery system based on NiCu nanoparticles for targeting various cells
    Stergar, Janja
    Ban, Irena
    Gradisnik, Lidija
    Maver, Uros
    [J]. JOURNAL OF SOL-GEL SCIENCE AND TECHNOLOGY, 2018, 88 (01) : 57 - 65
  • [44] Novel drug delivery system based on NiCu nanoparticles for targeting various cells
    Janja Stergar
    Irena Ban
    Lidija Gradišnik
    Uroš Maver
    [J]. Journal of Sol-Gel Science and Technology, 2018, 88 : 57 - 65
  • [45] Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment
    Venkatakrishnan, K.
    Obach, R. S.
    Rostami-Hodjegan, A.
    [J]. XENOBIOTICA, 2007, 37 (10-11) : 1225 - 1256
  • [46] Feasibility of combined biological treatments with omalizumab and non-IGE-targeting monoclonal antibodies: Novel insights and a mechanism-based approach
    Shamriz, O.
    Parnasa, E.
    Rubin, L.
    Talmon, A.
    Ribak, Y.
    Peleg, H.
    Confino-Cohen, R.
    Tal, Y.
    [J]. ALLERGY, 2023, 78 : 95 - 95
  • [47] Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events
    Shaffer, Christopher L.
    Scialis, Renato J.
    Rong, Haojing
    Obach, R. Scott
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (02) : 72 - 84
  • [48] Mapping Microenvironment-Mediated Signaling Dependency of Targeted Inhibitors: A Mechanism-Based Approach of Selecting Effective Therapy Targeting Drug Resistant AML
    Zeng, Zhihong
    Liu, Wenbin
    Tsao, Twee
    Qiu, Yihua
    Samudio, Ismael
    Baggerly, Keith
    Kornblau, Steven M.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Konopleva, Marina
    [J]. BLOOD, 2015, 126 (23)
  • [49] A HUMAN 3D CELL-BASED PLATFORM FOR DRUG DISCOVERY TARGETING PLASMODIUM HEPATIC INFECTION
    Rebelo, Sofia
    Arez, Francisca
    Fontinha, Diana
    Simao, Daniel
    Machado, Marta
    Martins, Tatiana
    Carrondo, Manuel
    Spangenberg, Thomas
    Brito, Catarina
    Greco, Beatrice
    Prudencio, Miguel
    Alves, Paula
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 99 (04): : 231 - 231
  • [50] Mechanism-based inactivation of human recombinant P4502C9 by the nonsteroidal anti-inflammatory drug suprofen
    O'Donnell, JP
    Dalvie, DK
    Kalgutkar, AS
    Obach, RS
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (11) : 1369 - 1377